GWLL.US Goldenwell Biotech Inc
- Market cap
- USD 59.4M
- P/E
- -
- P/B
- 5,175.12x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GWLL.US undervalued?
Graham numberThe Graham number of Goldenwell Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Goldenwell Biotech Inc fundamental analysis
No fundamental analysis for Goldenwell Biotech Inc yet.
Goldenwell Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Goldenwell Biotech Inc
Goldenwell Biotech, Inc. engages in the nutraceutical and dietary supplements business. It offers JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Solon, Ohio.
Full company profileGoldenwell Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Goldenwell Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 16.0K | 47.8K | 2.34K | 139.00 | 55.00 | -3.72K |
| Gross Profit | - | - | 8.39K | 25.2K | 1.11K | 64.00 | 12.00 | 24.00 |
| Operating Income | -7.80K | -6.37K | -118K | -985K | -117K | -123K | -113K | -132K |
| EBITDA | - | -6.37K | -118K | -985K | -1.07K | -123K | -113K | -101K |
| Net Income | -6.93K | -6.32K | -117K | -985K | -117K | -131K | -296K | -109K |
| EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||
| Total Assets | 247K | 249K | 461K | 248K | 228K | 224K | 36.1K | 29.0K |
| Total Liabilities | - | 0.00 | 159K | 46.8K | 143K | 271K | 380K | 427K |
| Shareholders' Equity | 247K | 249K | 302K | 202K | 84.7K | -47.2K | -344K | -344K |
| Cash & Short-term Investments | 247K | 249K | 214K | 46.0K | 53.2K | 49.4K | 26.8K | 26.8K |
| Total Debt | - | - | 47.8K | 25.4K | 142K | 95.6K | 95.6K | 327K |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.93K | -6.32K | -205K | -1.07M | -115K | -123K | -22.6K | 92.0K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 3.00 | 0.00 | 0.00 |
| Free Cash Flow | -6.93K | -6.32K | -205K | -1.07M | -115K | -123K | -22.6K | 92.0K |
| Ratios | ||||||||
| ROE | -2.8% | -2.5% | -38.8% | -488.6% | -138.0% | - | - | - |
| ROA | -2.8% | -2.5% | -25.4% | -396.6% | -51.3% | -58.7% | -820.8% | -376.0% |
| Net Profit Margin | - | - | -732.6% | -2,060.9% | -4,995.5% | -94,602.9% | -539,038.2% | - |
| Debt to Equity | - | - | 0.16x | 0.13x | 1.68x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Goldenwell Biotech Inc dividends
Goldenwell Biotech Inc has not paid dividends in the last 7 fiscal years.
Who owns Goldenwell Biotech Inc
- Insiders 83.84%
- Institutions 0.00%
- Public & others 16.16%
- Shares outstanding 99.0M
- Free float 16.0M
Goldenwell Biotech Inc company profile
- Company name
- Goldenwell Biotech Inc
- Ticker
- GWLL.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Food Products
- Fiscal year end
- December
- Address
- 7316 Capilano Dr., Solon, OH, United States, 44139
- Phone
- 440 666 7999
- Website
- goldenwellbiotech.com
About Goldenwell Biotech Inc
Goldenwell Biotech, Inc. engages in the nutraceutical and dietary supplements business. It offers JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Solon, Ohio.
Goldenwell Biotech Inc management
3- Mr. Shuang LiuChairman, CEO & President · born 1978
- Ms. Hua XieSecretary & Director · born 1970
- Mr. Lee YangTreasurer & Director · born 1969